This CPB has been revised to state that bendamustine is considered (i) medically necessary for adult T-cell leukemia/lymphoma, mycosis fungoides, peripheral T-cell lymphoma, primary cutaneous anaplastic large cell lymphoma (ALCL) with multifocal lesions and cutaneous ALCL with regional nodes (excludes systemic ALCL), Sezary syndrome, and small cell lung cancer, and (ii) experimental and investigational for melanoma.